ES2117049T3 - Procedimiento para la preparacion de una composicion terapeutica util frente a las carencias de magnesio y destinada a garantizar la liberacion del magnesio que contiene. - Google Patents
Procedimiento para la preparacion de una composicion terapeutica util frente a las carencias de magnesio y destinada a garantizar la liberacion del magnesio que contiene.Info
- Publication number
- ES2117049T3 ES2117049T3 ES92912677T ES92912677T ES2117049T3 ES 2117049 T3 ES2117049 T3 ES 2117049T3 ES 92912677 T ES92912677 T ES 92912677T ES 92912677 T ES92912677 T ES 92912677T ES 2117049 T3 ES2117049 T3 ES 2117049T3
- Authority
- ES
- Spain
- Prior art keywords
- magnesium
- weight
- release
- mgo
- therapeutic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011777 magnesium Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052749 magnesium Inorganic materials 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000008167 Magnesium Deficiency Diseases 0.000 title 1
- 235000004764 magnesium deficiency Nutrition 0.000 title 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 4
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- -1 fatty acid esters Chemical class 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229920001600 hydrophobic polymer Polymers 0.000 abstract 1
- MJMDTFNVECGTEM-UHFFFAOYSA-L magnesium dichloride monohydrate Chemical class O.[Mg+2].[Cl-].[Cl-] MJMDTFNVECGTEM-UHFFFAOYSA-L 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA NUEVA COMPOSICION UTIL FRENTE A CARENCIAS MAGNESICAS PARA LIBERAR POR VIA ENTERAL EL MAGNESIO QUE CONTIENE, DE MANERA LENTA Y CONTINUA, CARACTERIZANDOSE DICHA COMPOSICION EN QUE COMPRENDE UNA MEZCLA QUE TIENE, EN ASOCIACION CON UN EXCIPIENTE FISIOLOGICAMENTE ACEPTABLE, (A) 4 A 41 PARTES EN PESO DE MAGNESIO QUE PROCEDE DE UNA FUENTE DE MAGNESIO CONSTITUIDA POR NGO, MGCL2 Y LOS HIDRATOS DE CLORURO DE MAGNESIO DE FORMULA MGCL2, NH2O DONDE N ES UN NUMERO ENTERO O FRACCIONARIO SUPERIOR A 0 E INFERIOR O IGUAL A 6, Y (B) 6 A 13 PARTES EN PESO DE UN POLIMERO HIDROFILO, CUANDO LA FUENTE DE MG ES MGO, O 10 A 30 PARTES EN PESO DE UNA SUSTANCIA HIDROFOBA ELEGIDA ENTRE EL CONJUNTO CONSTITUIDO POR LOS POLIMEROS HIDROFOBOS FISIOLOGICAMENTE ACEPTABLES, LOS ESTERES DE ACIDO GRADO Y SUS MEZCLAS, CUANDO LA FUENTE DE MG ES DIFERENTE DE MGO, ESTANDO COMPRENDIDO SU CONTENIDO EN MG EN DICHA MEZCLA ENTRE 5 Y 60% EN PESO RESPECTO DEL PESO DE DICHA MEZCLA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9107141A FR2677546B1 (fr) | 1991-06-12 | 1991-06-12 | Composition therapeutique pour liberation prolonge de magnesium. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2117049T3 true ES2117049T3 (es) | 1998-08-01 |
Family
ID=9413736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92912677T Expired - Lifetime ES2117049T3 (es) | 1991-06-12 | 1992-06-12 | Procedimiento para la preparacion de una composicion terapeutica util frente a las carencias de magnesio y destinada a garantizar la liberacion del magnesio que contiene. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0542979B1 (es) |
| JP (1) | JPH06503096A (es) |
| AT (1) | ATE164071T1 (es) |
| DE (1) | DE69224793T2 (es) |
| DK (1) | DK0542979T3 (es) |
| ES (1) | ES2117049T3 (es) |
| FR (1) | FR2677546B1 (es) |
| WO (1) | WO1992022305A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
| FR2855412B1 (fr) * | 2003-05-27 | 2007-05-25 | Menvielle Bourg Fabienn Joanny | Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel |
| FR2931359B1 (fr) | 2008-05-20 | 2012-12-21 | Menvielle Bourg Fabienne Joanny | Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice |
| FR2931361B1 (fr) | 2008-05-20 | 2012-08-31 | Menvielle Bourg Fabienne Joanny | Systeme a base de magnesium et son utilisation en cosmetique |
| EP2813217A1 (fr) | 2013-06-11 | 2014-12-17 | Fabienne Joanny Menvielle-Bourg | Composition pour administration orale de magnésium, en association avec une composition destinée à traiter le diabète de type 2 ou ses complications |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422193A (en) * | 1974-07-26 | 1976-01-21 | Smith Kline French Lab | Pharmaceutical compositions |
| CH677612A5 (es) * | 1987-09-11 | 1991-06-14 | Ciba Geigy Ag | |
| GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
| US5002774A (en) * | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
-
1991
- 1991-06-12 FR FR9107141A patent/FR2677546B1/fr not_active Expired - Fee Related
-
1992
- 1992-06-12 ES ES92912677T patent/ES2117049T3/es not_active Expired - Lifetime
- 1992-06-12 AT AT92912677T patent/ATE164071T1/de not_active IP Right Cessation
- 1992-06-12 DE DE69224793T patent/DE69224793T2/de not_active Expired - Fee Related
- 1992-06-12 JP JP5500766A patent/JPH06503096A/ja active Pending
- 1992-06-12 WO PCT/FR1992/000534 patent/WO1992022305A1/fr active IP Right Grant
- 1992-06-12 EP EP92912677A patent/EP0542979B1/fr not_active Expired - Lifetime
- 1992-06-12 DK DK92912677T patent/DK0542979T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992022305A1 (fr) | 1992-12-23 |
| DE69224793T2 (de) | 1998-11-19 |
| ATE164071T1 (de) | 1998-04-15 |
| DE69224793D1 (de) | 1998-04-23 |
| EP0542979B1 (fr) | 1998-03-18 |
| JPH06503096A (ja) | 1994-04-07 |
| FR2677546A1 (fr) | 1992-12-18 |
| DK0542979T3 (da) | 1999-01-04 |
| FR2677546B1 (fr) | 1994-01-21 |
| EP0542979A1 (fr) | 1993-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2009890A1 (en) | Valproic acid | |
| BR9713199A (pt) | Péletes de desintegração rápida | |
| MX171463B (es) | Sistema de dosificacion de liberacion sostenida y procedimiento para su preparacion | |
| BR9713141A (pt) | Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos. | |
| ATE184598T1 (de) | Enniatine und enniatinderivate zur bekämpfung von endoparasiten | |
| YU46701B (sh) | Postupak u za dobijanje osnovnog nosećeg materijala za dozne oblike lekova sa produženim izdvajanjem aktivne supstance | |
| GB1520197A (en) | Stable antibiotic compositions | |
| KR880010759A (ko) | 방출 조절성 제제 | |
| IL85523A (en) | Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it | |
| DE69827143D1 (de) | Wässerige alkalimetallbicarbonat-lösungen zur benahdlung von osteoarthrose | |
| ES8802206A1 (es) | Procedimiento para la preparacion de microparticulas que permiten la liberacion prolongada de una substancia biologicameente activa. | |
| MY139606A (en) | Sustained-release composition and process for producing the same | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| AU8452991A (en) | 1-aryl-3-pyridinyl-2-propene-1-ones | |
| ES2117049T3 (es) | Procedimiento para la preparacion de una composicion terapeutica util frente a las carencias de magnesio y destinada a garantizar la liberacion del magnesio que contiene. | |
| US3594467A (en) | Long-lasting troche | |
| FR2712809B1 (fr) | Nouvelle composition pharmaceutique destinée à la préparation d'une poudre stable contenant, à titre d'ingrédient actif, une association d'acide acétylsalicylique et de métoclopramide. | |
| SE8702784D0 (sv) | Komposition | |
| CA2357114A1 (en) | Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder | |
| DE1292303T1 (de) | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält | |
| FR2604903B1 (fr) | Agents therapeutiques sous forme de particules submicroscopiques contre des parasitoses et compositions pharmaceutiques les contenant | |
| ES2042470T1 (es) | Producto para el tratamiento del cabello. | |
| AU8452791A (en) | 1-phenyl-3-aryl-2-propyne-1-ones | |
| CA2119661A1 (fr) | Nouveaux composes de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| JPS5531803A (en) | Polyamide composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 542979 Country of ref document: ES |